Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
暂无分享,去创建一个
Bingshu E. Chen | M. Federico | V. Kukreti | M. Crump | J. Kuruvilla | L. Shepherd | K. Imrie | R. Buckstein | R. Meyer | A. Turner | J. Sussman | T. Baetz | N. Di Renzo | S. Couban | L. Kaizer | K. Howson‐Jan | A. Hay | M. Rubinger | D. Macdonald | H. Olney | C. Kouroukis | M. Djurfeldt | M. Voralia
[1] KyungMann Kim,et al. Contrasting treatment‐specific survival using double‐robust estimators , 2012 .
[2] N. Schmitz,et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Paul Shinn,et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.
[4] A. Rosenwald,et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Alejandro Martín,et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study , 2008, Haematologica.
[7] V. Diehl,et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] D. Osoba,et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. , 2005, European journal of cancer.
[9] K. Ding,et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma , 2004, Cancer.
[10] S. Kvaløy,et al. ICE (ifosfamide, carboplatin, etoposide) as second‐line chemotherapy in relapsed or primary progressive aggressive lymphoma – the Nordic Lymphoma Group experience , 2004, European journal of haematology.
[11] K. Ding,et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] S. Bentley. WHO Classification of Tumours: Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[13] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Blay,et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. , 1998, Blood.
[15] A. Hagenbeek,et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Crump,et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] B. Zee,et al. 04 Measuring workload of cancer clinical trials: A multi-centre study by the clinical research associates (CRA) committee of the national cancer institute of Canada clinical trials group (NCIC CTG) , 1997 .
[18] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[19] D. Tulsky,et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[21] L. Freedman,et al. Allocation of patients to treatment groups in a controlled clinical study. , 1978, British Journal of Cancer.
[22] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[23] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[24] W. G. Cochran. Some Methods for Strengthening the Common χ 2 Tests , 1954 .